本文選題：非小細胞肺癌 + 胞苷脫氨酶��； 參考：《石河子大學》2017年碩士論文

【摘要】：目的:通過檢測新疆維吾爾族、漢族非小細胞肺癌患者外周血CDA A79C與G208A位點基因多態(tài)性,明確新疆維吾爾族與漢族非小細胞肺癌患者A79C與G208A位點基因型分布及基因頻率分布是否有民族差異性,并初步探討兩民族NSCLC患者基因多態(tài)性與化療療效的相關性,為兩民族非小細胞肺癌患者吉西他濱個體化治療提供理論依據(jù)。方法:收集2014年8月至2016年4月在石河子大學醫(yī)學院第一附屬醫(yī)院腫瘤內(nèi)科及喀什地區(qū)第一人民醫(yī)院經(jīng)病理學確診的晚期NSCLC初治維吾爾族患者53例,漢族患者67例;采用直接測序的方法檢測A79C與G208A的基因多態(tài)性,所有NSCLC患者均接受含吉西他濱方案的化療,化療兩周期后評效,分析兩民族的基因多態(tài)性分布差異及與吉西他濱化療療效的相關性。結(jié)果:(1)53例維吾爾族、67例漢族NSCLC患者CDA A79C與G208A基因型頻率均符合Hardy-Weinberg平衡(P0.05);(2)新疆維吾爾族、漢族NSCLC患者一般臨床資料對比,P0.05無統(tǒng)計學差異性;對CDA A79C分析:漢族中突變基因型頻率為47.8%,突變等位基因頻率為32.8%,維吾爾族中突變基因型頻率為24.6%,突變等位基因頻率為5.1%,且兩組在基因型頻率與等位基因頻率均有統(tǒng)計學意義(P0.05)。對CDA G208A分析:兩組中均未檢測出基因型AA,漢族中突變基因型頻率為22.4%,突變等位基因頻率為11.2%,維吾爾族中突變基因型頻率為5.7%,突變等位基因頻率為2.8%,且兩組在基因型頻率與等位基因頻率均有統(tǒng)計學意義(P0.05)。(3)在A79C基因AC基因型中,漢族有效率為35%,維族有效率為30%,漢族與維吾爾族NSCLC的臨床療效有統(tǒng)計學差異(P=0.028)。在G208A基因GG基因型中,漢族有效率為55.8%,維族有效率為32%,漢族與維吾爾族NSCLC的臨床療效有統(tǒng)計學差異(P=0.016)。(4)漢族NSCLC患者A79C基因AA、AC、CC基因型化療有效率分別為65.7%、35%、25%,此基因與化療療效有統(tǒng)計學差異(P=0.016)。維吾爾族NSCLC患者A79C基因AA、AC、CC基因型化療有效率分別為62.5%、30%、0,此基因與化療療效有統(tǒng)計學差異(P=0.031)。結(jié)論:1.在NSCLC患者中,維吾爾族、漢族CDA A79C與G208A這兩個位點的基因多態(tài)性存在種族差異性;2.在維、漢兩民族非小細胞肺癌患者A79C基因AC基因型與G208A基因GG基因型中,均為漢族療效優(yōu)于維吾爾族NSCLC患者療效。3.維、漢兩民族非小細胞肺癌患者A79C多態(tài)性與化療效果密切相關,且AA基因型化療療效優(yōu)于AC、CC基因型的化療療效,可能對今后兩民族NSCLC患者個體化化療具有潛在的應用價值,為臨床個體化用藥提供參考。
[Abstract]:Objective: to detect the polymorphisms of CDA A79C and G208A loci in peripheral blood of Xinjiang Uygur and Han non-small cell lung cancer patients.To determine whether there are ethnic differences in genotype distribution and gene frequency distribution of A79C and G208A loci between Uygur and Han non-small cell lung cancer patients in Xinjiang, and to explore the correlation between gene polymorphism and chemotherapy efficacy in patients with NSCLC.To provide theoretical basis for the individualized treatment of gemcitabine in patients with non-small cell lung cancer (NSCLC).Methods: from August 2014 to April 2016, 53 patients with advanced Uygur nationality and 67 patients with Han nationality who were diagnosed pathologically in Department of Oncology, the first affiliated Hospital of Shihezi University Medical College and the first people's Hospital of Kashi region were collected.The gene polymorphisms of A79C and G208A were detected by direct sequencing. All patients with NSCLC received chemotherapy with gemcitabine regimen, and the efficacy was evaluated after two cycles of chemotherapy.To analyze the difference of gene polymorphism distribution between the two peoples and the relationship between the gene polymorphism and the efficacy of gemcitabine chemotherapy.Results the frequencies of CDA A79C and G208A genotypes in 53 cases of Uygur nationality and 67 cases of Han nationality with NSCLC were in accordance with the frequency of Hardy-Weinberg balance (P0.05P0.05P0.05P0.05P0.05P0.05) there was no significant difference in the general clinical data between Xinjiang Uygur and Han nationality NSCLC patients (P0.05).The analysis of CDA A79C showed that the frequency of mutation genotype was 47.8, the frequency of mutation allele was 32.8in Han nationality, the frequency of mutation genotype was 24.6in Uygur, the frequency of mutation allele was 5.1g, and the frequency of genotype and allele was statistically significant in both groups (P 0.05).Analysis of CDA G208A: no genotypes were detected in the two groups, the frequency of mutation genotype was 22.4in Han nationality, the frequency of mutation allele was 11.2um, the frequency of mutation genotype was 5.7g and the frequency of mutation allele was 2.8in Uygur nationality, and the frequency of mutation allele was 2.8g in the two groups.Type A frequency and allele frequency were statistically significant in A79C gene AC genotype.The effective rates of Han and Uygur were 35 and 30 respectively. The clinical efficacy of NSCLC in Han nationality and Uygur nationality was significantly different from that in Uygur nationality.In the GG genotype of G208A gene,The effective rate of A79C gene in NSCLC patients of Han nationality was 55.8%, and that of Uygur nationality was 325.The effective rate of A79C gene was 55.8% and the effective rate of Uygur nationality was 325.The effective rate of A79C gene was 65.78% and the effective rate of Uygur nationality was 325.The effective rate of A79C gene was 65.7% and 35% (P 0.016%) respectively in NSCLC patients of Han nationality and Uygur nationality, and there was a significant difference between this gene and chemotherapy effect (P0.016).The effective rates of A79C gene ACCC genotype chemotherapy in Uygur NSCLC patients were 62.5% and 30%, respectively. There was statistical difference between A79C gene and chemotherapy effect.Conclusion 1.In NSCLC patients, the genetic polymorphisms of CDA A79C and G208A in Uygur and Han nationality were different from each other.A79C gene AC genotype and G208A gene GG genotype in patients with non-small cell lung cancer (NSCLC) of both nationalities in Uygur and Han nationalities were better than that in Uygur NSCLC patients by using A79C gene AC genotype and G208A gene GG genotype.The A79C polymorphism in patients with non-small cell lung cancer (NSCLC) of both nationalities was closely related to the effect of chemotherapy, and the efficacy of AA genotype chemotherapy was better than that of ACCC genotype, which may have potential application value for individualized chemotherapy in NSCLC patients of both nationalities in the future.To provide a reference for clinical individualized drug use.
【學位授予單位】：石河子大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R734.2

【參考文獻】

相關期刊論文 前10條

1 阿提坎·卡吾力;張淑娟;王磊;克尤木·阿不來提;常建華;;新疆維吾爾族非小細胞肺癌表皮生長因子受體基因突變與病理特征的相關性研究[J];中國醫(yī)藥導報;2016年32期

2 馬玲;張琰;單莉;韓志剛;;維吾爾族晚期非小細胞肺癌患者EGFR、KRAS基因突變狀態(tài)及其與TKI靶向治療效果的關系[J];山東醫(yī)藥;2016年31期

3 申紅麗;張嶠;單莉;;新疆維吾爾族與漢族非小細胞肺癌EGFR突變和HER2過表達的差異及相關性[J];現(xiàn)代腫瘤醫(yī)學;2013年12期

4 張思維;陳萬青;鄭榮壽;李霓;曾紅梅;李光琳;魏文強;趙平;;2003～2007年中國癌癥死亡分析[J];中國腫瘤;2012年03期

5 吳菲;林國楨;張晉昕;;我國惡性腫瘤發(fā)病現(xiàn)狀及趨勢[J];中國腫瘤;2012年02期

6 董志君;;非小細胞肺癌患者外周血胞苷脫氨酶的表達與吉西他濱化療敏感性的關系研究[J];現(xiàn)代實用醫(yī)學;2011年11期

7 張亞琨;郭其森;;非小細胞肺癌的化療進展[J];中國醫(yī)藥科學;2011年15期

8 陳瑩;錢曉萍;劉寶瑞;;非小細胞肺癌吉西他濱藥物耐藥相關基因研究進展[J];中國肺癌雜志;2011年05期

9 郭其森;;非小細胞肺癌內(nèi)科治療的現(xiàn)狀[J];中華腫瘤防治雜志;2009年10期

10 支修益;;我國肺癌流行病學現(xiàn)狀分析[J];中國處方藥;2009年02期

相關碩士學位論文 前1條

1 張璇;核糖核苷酸還原酶（RRM1）37位點基因多態(tài)性與晚期非小細胞肺癌患者GP方案化療敏感性關系的研究[D];遼寧醫(yī)學院;2012年

，

本文編號：1765223